Applying TLR synergy in immunotherapy: Implications in cutaneous leishmaniasis

Journal of Immunology

Volumn 185, Issue 3, 2010, Pages 1701-1710

  Raman, Vanitha S ^a   Bhatia, Ajay ^a   Picone, Alex ^a   Whittle, Jacqueline ^a   Bailor, Hilton R ^a   O'Donnell, Joanne ^a   Pattabhi, Sowmya ^a   Guderian, Jeffrey A ^a   Mohamath, Raodoh ^a   Duthie, Malcolm S ^a   Reed, Steven G ^a  

^a INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LEISHMANIA VACCINE; LEISHMANIA VACCINE L110F; LIPID; PHOSPHORYL LIPID A; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIGEN L; BACTERIAL ANTIGEN; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; CYTOSKELETON PROTEIN; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; LIPID A; LIPOPOLYSACCHARIDE; MARENOSTRIN; OLIGODEOXYRIBONUCLEOTIDE; TOLL LIKE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG FORMULATION; DRUG POTENTIATION; EFFECTOR CELL; FEMALE; IMMUNOTHERAPY; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; SKIN LEISHMANIASIS; L110F; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; DRUG COMBINATION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BONE MARROW CELLS; CELLS, CULTURED; CYTOSKELETAL PROTEINS; DRUG THERAPY, COMBINATION; FEMALE; INTERLEUKIN-12; LEISHMANIASIS, CUTANEOUS; LIPID A; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; TOLL-LIKE RECEPTORS;

EID: 77956404315     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000238     Document Type: Article

References (61)

1. Stuart, K., A. Fairlamb, D. Zilberstein, S. L. Croft, A. Dessein, D. McMahon-Pratt, P. Launois, J. Louis, D. Sacks, S. G. Reed, I. Guizani, et al. 2004. Scientific Working Group on Leishmaniasis Meeting Report, February 2-4. Geneva, Switzerland, p. 35-143. Available at: http://apps.who.int/tdr/svc/ publications/tdrresearch-publications/swg-report-leishmaniasis.
2. Ghalib, H., and F. Modabber. 2007. Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis. Kinetoplastid Biol. Dis. 6: 7.
3. Zijlstra, E. E., A. M. Musa, E. A. Khalil, I. M. el-Hassan, and A. M. el-Hassan. 2003. Post-kala-azar dermal leishmaniasis. Lancet Infect. Dis. 3: 87-98.
4. Firdous, R., M. Yasinzai, and K. Ranja. 2009. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis. Int. J. Dermatol. 48: 758-762.
5. Choudhury, K., D. Zander, M. Kube, R. Reinhardt, and J. Clos. 2008. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int. J. Parasitol. 38: 1411-1423.
6. Ouellette, M., J. Drummelsmith, and B. Papadopoulou. 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Updat. 7: 257-266.
7. Noazin, S., F. Modabber, A. Khamesipour, P. G. Smith, L. H. Moulton, K. Nasseri, I. Sharifi, E. A. Khalil, I. D. Bernal, C. M. Antunes, et al. 2008. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26: 6759-6767.
8. Hoare, C. A. 1943. Comment on Dubovsky, P., Vaccinotherapy in cutaneous leishmaniais. Trop. Dis. Bull. 40: 297.
9. Genaro, O., V. P. de Toledo, C. A. da Costa, M. V. Hermeto, L. C. Afonso, and W. Mayrink. 1996. Vaccine for prophylaxis and immunotherapy, Brazil. Clin. Dermatol. 14: 503-512.
10. Greenblatt, C. L. 1980. The present and future of vaccination for cutaneous leishmaniasis. Prog. Clin. Biol. Res. 47: 259-285.
11. Palatnik-de-Sousa, C. B. 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26: 1709-1724.
12. Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21: 244-249.
13. Buates, S., and G. Matlashewski. 1999. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J. Infect. Dis. 179: 1485-1494.
14. Coler, R. N., Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75: 4648-4654.
15. Bertholet, S., Y. Goto, L. Carter, A. Bhatia, R. F. Howard, D. Carter, R. N. Coler, T. S. Vedvick, and S. G. Reed. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
16. Campos-Neto, A., R. Porrozzi, K. Greeson, R. N. Coler, J. R. Webb, Y. A. Seiky, S. G. Reed, and G. Grimaldi, Jr. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69: 4103-4108.
17. Reed, S. G., R. N. Coler, and A. Campos-Neto. 2003. Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev. Vaccines 2: 239-252.
18. Walker, P. S., T. Scharton-Kersten, A. M. Krieg, L. Love-Homan, E. D. Rowton, M. C. Udey, and J. C. Vogel. 1999. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc. Natl. Acad. Sci. USA 96: 6970-6975.
19. Flynn, B., V. Wang, D. L. Sacks, R. A. Seder, and D. Verthelyi. 2005. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs. Infect. Immun. 73: 4948-4954.
20. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850.
21. Coler, R. N., Y. A. Skeiky, K. Bernards, K. Greeson, D. Carter, C. D. Cornellison, F. Modabber, A. Campos-Neto, and S. G. Reed. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70: 4215-4225.
22. Velez, I. D., K. Gilchrist, S. Martinez, J. R. Ramirez-Pineda, J. A. Ashman, F. P. Alves, R. N. Coler, L. Y. Bogatzki, S. J. Kahn, A. M. Beckmann, et al. 2009. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine 28: 329-337.
23. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8: 247-258.
24. Row, R. 1912. The curative value of Leishmania culture "vaccine" in oriental sore. Br. Med. J. 1: 540-541.
25. Badaro, R., I. Lobo, A. Munos, E. M. Netto, F. Modabber, A. Campos-Neto, R. N. Coler, and S. G. Reed. 2006. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194: 1151-1159.
26. Badaro, R., I. Lobo, M. Nakatani, A. Muiños, E. M. Netto, R. N. Coler, and S. G. Reed. 2001. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz. J. Infect. Dis. 5: 223-232.
27. Baldwin, S. L., S. Bertholet, M. Kahn, I. Zharkikh, G. C. Ireton, T. S. Vedvick, S. G. Reed, and R. N. Coler. 2009. Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine 27: 3063-3071.
28. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rössner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
29. Scott, P. 1991. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J. Immunol. 147: 3149-3155.
30. Afonso, L. C., T. M. Scharton, L. Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
31. Park, A. Y., B. D. Hondowicz, and P. Scott. 2000. IL-12 is required to maintain a Th1 response during Leishmania major infection. J. Immunol. 165: 896-902. (Pubitemid 30484757)
32. Martin, M., S. M. Michalek, and J. Katz. 2003. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect. Immun. 71: 2498-2507.
33. Anderson, R. C., C. B. Fox, T. S. Dutill, N. Shaverdian, T. L. Evers, G. R. Poshusta, J. Chesko, R. N. Coler, M. Friede, S. G. Reed, and T. S. Vedvick. 2009. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123-132.
34. Baldwin, S. L., N. Shaverdian, Y. Goto, M. S. Duthie, V. S. Raman, T. Evers, F. Mompoint, T. S. Vedvick, S. Bertholet, R. N. Coler, and S. G. Reed. 2009. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 27: 5956-5963.
35. Napolitani, G., A. Rinaldi, F. Bertoni, F. Sallusto, and A. Lanzavecchia. 2005. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6: 769-776.
36. + T-cell subsets in the regulation of parasite immunity and disease. Immunol. Rev. 112: 161-182.
37. Nabors, G. S., L. C. Afonso, J. P. Farrell, and P. Scott. 1995. Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam. Proc. Natl. Acad. Sci. USA 92: 3142-3146.
38. Da CostaSantiago, H., C. F. Oliveira, L. Santiago, F. O. Ferraz, D. G. de Souza, L. A. de-Freitas, L. C. Afonso, M. M. Teixeira, R. T. Gazzinelli, and L. Q. Vieira. 2004. Involvement of the chemokine RANTES (CCL5) in resistance to experimental infection with Leishmania major. Infect. Immun. 72: 4918-4923.
39. Katzman, S. D., and D. J. Fowell. 2008. Pathogen-imposed skewing of mouse chemokine and cytokine expression at the infected tissue site. J. Clin. Invest. 118: 801-811.
40. Filipe-Santos, O., P. Pescher, B. Breart, C. Lippuner, T. Aebischer, N. Glaichenhaus, G. F. Späth, and P. Bousso. 2009. A dynamic map of antigen recognition by CD4 T cells at the site of Leishmania major infection. Cell Host Microbe 6: 23-33.
41. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20: 197-216.
42. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
43. Trinchieri, G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14: 335-338. (Pubitemid 23198164)
44. Convit, J., P. L. Castellanos, A. Rondon, M. E. Pinardi, M. Ulrich, M. Castes, B. Bloom, and L. Garcia. 1987. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 329: 401-405. (Pubitemid 17016578)
45. Badaro, R., and W. D. Johnson, Jr. 1993. The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis. J. Infect. Dis. 167 (Suppl. 1): S13-S17.
46. Gurunathan, S., C. Prussin, D. L. Sacks, and R. A. Seder. 1998. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4: 1409-1415.
47. Uzonna, J. E., and P. A. Bretscher. 2001. Anti-IL-4 antibody therapy causes regression of chronic lesions caused by medium-dose Leishmania major infection in BALB/c mice. Eur. J. Immunol. 31: 3175-3184.
48. Kropf, P., M. A. Freudenberg, M. Modolell, H. P. Price, S. Herath, S. Antoniazi, C. Galanos, D. F. Smith, and I. Müller. 2004. Toll-like receptor 4 contributes to efficient control of infection with the protozoan parasite Leishmania major. Infect. Immun. 72: 1920-1928.
49. Antoniazi, S., H. P. Price, P. Kropf, M. A. Freudenberg, C. Galanos, D. F. Smith, and I. Müller. 2004. Chemokine gene expression in Toll-like receptor-competent and -deficient mice infected with Leishmania major. Infect. Immun. 72: 5168-5174.
50. Sugita, K., K. Kabashima, K. Atarashi, T. Shimauchi, M. Kobayashi, and Y. Tokura. 2007. Innate immunity mediated by epidermal keratinocytes promotes acquired immunity involving Langerhans cells and T cells in the skin. Clin. Exp. Immunol. 147: 176-183.
51. Li, Y., K. Ishii, H. Hisaeda, S. Hamano, M. Zhang, K. Nakanishi, T. Yoshimoto, H. Hemmi, K. Takeda, S. Akira, et al. 2004. IL-18 gene therapy develops Th1- type immune responses in Leishmania major-infected BALB/c mice: is the effect mediated by the CpG signaling TLR9? Gene Ther. 11: 941-948.
52. Zhang, W. W., and G. Matlashewski. 2008. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect. Immun. 76: 3777-3783.
53. Bagchi, A., E. A. Herrup, H. S. Warren, J. Trigilio, H. S. Shin, C. Valentine, and J. Hellman. 2007. MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J. Immunol. 178: 1164-1171. (Pubitemid 46095190)
54. Vanhoutte, F., C. Paget, L. Breuilh, J. Fontaine, C. Vendeville, S. Goriely, B. Ryffel, C. Faveeuw, and F. Trottein. 2008. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol. Lett. 116: 86-94.
55. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550.
56. Whitmore, M. M., M. J. DeVeer, A. Edling, R. K. Oates, B. Simons, D. Lindner, and B. R. Williams. 2004. Synergistic activation of innate immunity by doublestranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 64: 5850-5860.
57. Arevalo, I., B. Ward, R. Miller, T. C. Meng, E. Najar, E. Alvarez, G. Matlashewski, and A. Llanos-Cuentas. 2001. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33: 1847-1851.
58. El-On, J., E. Bazarsky, and R. Sneir. 2007. Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator imiquimod. Exp. Parasitol. 116: 156-162.
59. Murray, H. W., J. D. Berman, and S. D. Wright. 1988. Immunochemotherapy for intracellular Leishmania donovani infection: gamma interferon plus pentavalent antimony. J. Infect. Dis. 157: 973-978.
60. Miranda-Verastegui, C., G. Tulliano, T. W. Gyorkos, W. Calderon, E. Rahme, B. Ward, M. Cruz, A. Llanos-Cuentas, and G. Matlashewski. 2009. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist Imiquimod in combination with pentavalent antimony. PLoS Negl. Trop. Dis. 3: e491.
61. Mantovani, A., R. Bonecchi, and M. Locati. 2006. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6: 907-918.